Computer-based simulation for drug development
Company 2021
VeriSIM Life, San Francisco, USA
In the present study, a patented biosimulation software platform (BIOiSIM) for optimizing drug development is presented. Pharmacokinetic (PK) predictions based on traditional in vivo studies are time-consuming, costly and characterized by high susceptibility to error. By simulating (personalized) plasma concentrations, the new computer software makes it possible to calculate a data set with all relevant information about the absorption, distribution, metabolism, and excretion of a new active substance (ADME) in up to 5 hours. Based on the results of the study, the predictions on the efficacy and toxicity of new drugs have been demonstrably improved by the analysis and optimization of PK-relevant parameters, in particular the specific plasma partition coefficients (Kp) for organs and tissues. The AI-supported method thus reduces the health risk for subjects in clinical trials and, in parallel, generates a valid database of global drug dispositions for future drug development through the integration of mechanistic models and machine learning.
A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning integrated modeling platform
Jyotika Varshney
Added on: 08-02-2022
[1] https://www.nature.com/articles/s41598-021-90637-1#MOESM1
